Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive Non-Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence

Clin Pharmacol Ther. 2021 Nov;110(5):1162-1163. doi: 10.1002/cpt.2373. Epub 2021 Aug 8.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Carbazoles / adverse effects
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Piperidines
  • Receptor Protein-Tyrosine Kinases

Substances

  • Carbazoles
  • Piperidines
  • Receptor Protein-Tyrosine Kinases
  • alectinib

Grants and funding